AMI Asset Management Corp Has $1.73 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

AMI Asset Management Corp raised its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 50.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 77,688 shares of the company's stock after acquiring an additional 26,010 shares during the period. AMI Asset Management Corp owned about 0.11% of Kiniksa Pharmaceuticals International worth $1,725,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. Asset Management One Co. Ltd. acquired a new position in Kiniksa Pharmaceuticals International in the first quarter valued at about $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals International in the first quarter valued at about $42,000. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $61,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $158,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Ross Moat sold 23,234 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $28.02, for a total value of $651,016.68. Following the transaction, the insider now owns 9,415 shares of the company's stock, valued at approximately $263,808.30. This represents a 71.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eben Tessari sold 12,000 shares of the company's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the transaction, the chief operating officer now directly owns 77,363 shares in the company, valued at $1,584,394.24. The trade was a 13.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 440,863 shares of company stock valued at $12,101,029 over the last 90 days. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Stock Performance

KNSA traded down $0.45 on Friday, hitting $28.04. 8,681,337 shares of the company were exchanged, compared to its average volume of 547,399. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.38 and a 12 month high of $30.69. The company has a market cap of $2.05 billion, a PE ratio of -112.16 and a beta of 0.06. The stock's fifty day moving average is $26.79 and its 200-day moving average is $22.66.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The business's revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.25) earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Citigroup assumed coverage on Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target on the stock. Wedbush reiterated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $38.80.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.